CEO and co-founder of RxAll, Adebayo Alonge, has led his startup to win the 2019 Hello Tomorrow deepTech contest. He competed alongside 4500 deepTech startups from across 119 countries in the world to win the grand prize of €100,000. He is the first African to win this contest. The Grand Finals took place in Paris on March 13-15th during the Hello Tomorrow Global Summit. There were 80 finalists in 12 categories that made to the Grand Finals in Paris, France.
The Hello Tomorrow Global Challenge is a worldwide renowned science & technology startup competition designed specifically to address the needs of deeptech entrepreneurs across several different industries and technologies.
[#BNPPEvent] When #deeptech finds its way to a #safer future: Today, half of drugs in Africa are fake drugs. But tomorrow, thanks to @RxAll_Inc & @adebayoalonge, handheld nanoscanners can ensure drug quality in real time! They won BNP Paribas Grand Prize at @hellotmrc: € 100K
pic.twitter.com/uSnhnrCLVp
— BNP Paribas Group (@BNPParibas) March 19, 2019
RxAll is an AI-hyperspectral Platform for Authenticating Drugs. The platform uses a proprietary molecular sensor device with a cloud-based IP-protected AI algorithm and database of spectral signatures of drugs- both prescription and recreational- to carry out non-destructive drug authentication.
RxAll works with drug regulators and other stakeholders to reduce branded drug counterfeiting and ensure that patients receive high quality authenticated drugs. Pharma manufacturers increase sales and patients have better access to high quality drugs.
Created in 2013 by deeptech entrepreneur Xavier Duportet and Arnaud De La Tour, the Hello Tomorrow deepTech Challenge gives scientists and deeptech entrepreneurs around the globe a platform for their research and projects, providing equity-free prize money as well as other funding opportunities, global visibility and connections with key players in the deeptech innovation network.
RxAll is currently operational in Canada, China, Myanmar, Kenya, Uganda, Ghana and Nigeria.
